Physician profile
Frank David Wright
NPI 1689638884
$9,713.09
in general payments reported to CMS, 2019-2025
35 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $521 · 2020: $890 · 2021: $1,113 · 2022: $1,902 · 2023: $1,695 · 2024: $1,981 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,286.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,304.56 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,317.55 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $956.91 | 2019-2025 | Tremfya, Stelara, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $730.06 | 2019-2025 | Xifaxan, Trulance |
| Celgene Corporation | $378.38 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $274.22 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $220.45 | 2023-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $219.12 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $211.30 | 2020-2023 | Ocaliva |
| Daiichi Sankyo INC. | $167.97 | 2019-2025 | Injectafer |
| Nestle Healthcare Nutrition INC. | $163.55 | 2021-2023 | |
| Pfizer INC. | $158.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $152.79 | 2019-2023 | Dificid |
| Genzyme Corporation | $152.41 | 2022-2024 | |
| Qol Medical, LLC | $127.96 | 2023-2025 | Sucraid, Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $121.17 | 2022-2023 | Spyglass, Exalt Model D |
| Regeneron Healthcare Solutions, INC. | $111.56 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $96.18 | 2020-2023 | Linzess |
| Janssen Scientific Affairs, LLC | $96.17 | 2021 | |
| Organon LLC | $94.71 | 2023-2024 | Hadlima, Renflexis |
| Novo Nordisk INC | $88.72 | 2022-2025 | Wegovy |
| Redhill Biopharma INC. | $75.50 | 2020-2022 | |
| Lilly USA, LLC | $74.94 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $62.54 | 2023-2025 | Ibsrela |
| Evoke Pharma, INC. | $57.24 | 2022-2023 | Gimoti |
| Ferring Pharmaceuticals INC. | $55.24 | 2023-2024 | Rebyota |
| Allergan, INC. | $52.26 | 2020 | |
| Madrigal Pharmaceuticals | $43.55 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $36.86 | 2022-2023 | Suflave, Sutab |
| Medtronic, INC. | $21.70 | 2021 | |
| Alfasigma USA, INC. | $21.41 | 2020 | |
| Qiagen, LLC | $19.85 | 2020 | |
| Shire North American Group INC | $18.96 | 2019 | |
| Amgen INC. | $15.21 | 2023 | Avsola, Amjevita |
| Capsovision, INC. | $13.78 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.